Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 11/2014

Open Access 01-11-2014 | Original Article

Mannose-Binding Lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours

Authors: Anna St. Swierzko, Agnieszka Szala, Sambor Sawicki, Janusz Szemraj, Marcin Sniadecki, Anna Sokolowska, Andrzej Kaluzynski, Dariusz Wydra, Maciej Cedzynski

Published in: Cancer Immunology, Immunotherapy | Issue 11/2014

Login to get access

Abstract

Mannose-Binding Lectin (MBL) is a serum pattern recognition molecule, able to activate complement in association with MASP proteases. Serum levels of MBL and MASP-2, activities of MBL–MASP complexes, single nucleotide polymorphisms of the MBL2 and MASP2 genes and/or their specific mRNA expression in ovarian sections were investigated in 128 patients suffering from primary ovarian cancer (OC) and compared with 197 controls (C), encompassing both patients with benign ovarian tumours (n = 123) and others with no ovarian pathology (n = 74). MBL deficiency-associated genotypes were more common among OC patients than among controls. The O/O group of genotypes was associated with ovarian cancer (OR 3.5, p = 0.02). In A/A homozygotes, MBL concentrations and activities were elevated in the OC group and correlated with C-reactive protein. Moreover, high MBL serum levels were associated with more advanced disease stage. No differences in distribution of the MASP2 +359 A>G (D120G) SNP or MASP-2 serum levels were found between cancer patients and their controls. However, the highest frequency of the A/G (MASP2) and LXA/O or O/O (MBL2) genotypes was found among OC patients with tumours of G1–2 grade (well/moderately differentiated). Furthermore, MBL deficiency-associated genotypes predicted prolonged survival. None of the parameters investigated correlated with CA125 antigen or patients’ age. The local expression of MBL2 and MASP2 genes was higher in women with ovarian cancer compared with controls. It is concluded that the expression of MBL and MASP-2 is altered in ovarian cancer, possibly indicating involvement of the lectin pathway of complement activation in the disease.
Appendix
Available only for authorised users
Literature
1.
Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SR, Koutoulaki A, Gerard C, Coukos G, Lambris JD (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9:1225–1235PubMedCrossRefPubMedCentral
2.
Ma Y, Uemura K, Oka S, Kozutsumi Y, Kawasaki N, Kawasaki T (1999) Antitumor activity of mannan-binding protein in vivo as revealed by a virus expression system: Mannan-binding protein-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci 96:371–375PubMedCrossRefPubMedCentral
3.
Swierzko AS, Kilpatrick DC, Cedzynski M (2013) Mannan-binding lectin in malignancy. Mol Immunol 55:16–21PubMedCrossRef
4.
MacDonald SL, Downing I, Atkinson AP, Gallagher RC, Turner ML, Kilpatrick DC (2010) Dendritic cells previously exposed to mannan-binding lectin enhance cytokine production in allogeneic mononuclear cell cultures. Hum Immunol 71:1077–1083PubMedCrossRef
5.
Wang Y, Chen AD, Lei YM, Shan GQ, Zhang LY, Lu X, Chen ZL (2013) Mannose-binding lectin inhibits monocyte proliferation trough Transforming Growth Factor-β1 and p38 signaling pathways. PLoS ONE 8:e72505PubMedCrossRefPubMedCentral
6.
Hummelshoj T, Munthe-Fog L, Madsen HO, Sim RB, Garred P (2008) Comparative study of the human ficolins reveals unique features of ficolin-3 (Hakata antigen). Mol Immunol 45:1623–1632PubMedCrossRef
7.
Swierzko AS, Florczak K, Cedzynski M, Szemraj J, Wydra D, Bak-Romaniszyn L, Emerich J, Sulowska Z (2007) Mannan-binding lectin (MBL) in women with tumours of the reproductive system. Cancer Immunol Immunother 56:959–971PubMedCrossRef
8.
Arai T, Tabona P, Summerfield JA (1993) Human mannose-binding protein gene is regulated by interleukins, dexamethasone and heat shock. Q J Med 86:575–582PubMed
9.
Sorensen CM, Hansen TK, Steffensen R, Jensenius JC, Thiel S (2006) Hormonal regulation of mannan-binding lectin synthesis in hepatocytes. Clin Exp Immunol 145:173–182PubMedCrossRefPubMedCentral
10.
Stover C, Endo Y, Takahashi M, Lynch NJ, Constantinescu C, Vorup-Jensen T, Thiel S, Friedl H, Hakeln T, Hall R, Gregory S, Fujita T, Schwaeble W (2001) The human gene for mannan-binding lectin-associated serine protease-2 (MASP-2), the effector component of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2-3. Genes Immun 2:119–127PubMedCrossRef
11.
Thiel S, Steffensen R, Christensen IJ, Ip WK, Lau YL, Reason IJ, Eiberg H, Gadjeva M, Ruseva M, Jensenius JC (2007) Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes Immun 8:154–163PubMedCrossRef
12.
Degn SE, Jensen L, Hansen AG, Duman D, Tekin M, Jensenius JC, Thiel S (2012) Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J Immunol 189:3957–3969PubMedCrossRef
13.
Heja D, Kocsis A, Dobo J, Szilagyi K, Szasz R, Zavodszky P, Pal G, Gal P (2012) Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proc Natl Acad Sci USA 109:10498–10503PubMedCrossRefPubMedCentral
14.
Megyeri M, Harmat V, Major B, Vegh A, Balczer J, Heja D, Szilagyi K, Datz D, Pal G, Zavodszky P, Gal P, Dobo J (2013) Quantitative characterization of the activation steps of mannan-binding lectin (MBL)-associated serine proteases (MASPs) points to the central role of MASP-1 in the initiation of complement lectin pathway. J Biol Chem 288:8922–8934PubMedCrossRefPubMedCentral
15.
Yongqing T, Dretin N, Duncan RD, Wijeyewickrema LC, Pike RN (2012) Mannose-binding lectin serine proteases and associated proteins of the lectin pathway of complement: two genes, five proteins and many functions ? Biochim Biophys Acta 1824:253–262PubMedCrossRef
16.
Matsushita M, Endo Y, Fujita T (2013) Structural and functional overview of the lectin complement pathway: its molecular basis and physiological implication. Arch Immunol Ther Exp 61:273–283CrossRef
17.
Dobo J, Major B, Kekesi KA, Szabo I, Megyeri M, Hajela K, Juhasz G, Zavodszky P, Gal P (2011) Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS ONE 6:e20036PubMedCrossRefPubMedCentral
18.
19.
Lynch NJ, Khan SU, Stover CM, Sandrini SM, Marston D, Presanis JS, Schwaeble WJ (2005) Composition of the lectin pathway of complement in Gallus gallus: absence of mannan-binding lectin-associated serine protease-1 in birds. J Immunol 174:4998–5006PubMedCrossRef
20.
Seyfarth J, Garred P, Madsen HO (2006) Extra-hepatic transcription of the human mannose-binding lectin gene (mbl2) and the MBL-associated serine protease 1-3 genes. Mol Immunol 43:962–971PubMedCrossRef
21.
Endo Y, Takahashi M, Kuraya M, Matsushita M, Stover CM, Schwaeble WJ, Fujita T (2002) Functional characterization of human mannose-binding lectin-associated serine protease (MASP)-1/3 and MASP-2 promoters, and comparison with the C1 s promoter. Int Immunol 14:1193–1201PubMedCrossRef
22.
Szala A, Sawicki S, ASt Swierzko, Szemraj J, Sniadecki M, Michalski M, Kaluzynski A, Lukasiewicz J, Maciejewska A, Wydra D, Kilpatrick DC, Cedzynski M (2013) Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours. Cancer Immunol Immunother 62:1411–1419PubMedCrossRefPubMedCentral
23.
Cedzynski M, Szemraj J, Swierzko AS, Bak-Romaniszyn L, Banasik M, Zeman K, Kilpatrick DC (2004) Mannan-binding lectin insufficiency in children with recurrent infections of the respiratory system. Clin Exp Immunol 136:304–311PubMedCrossRefPubMedCentral
24.
Swierzko ASt, Cedzynski M, Domzalska-Popadiuk I, MacDonald SL, Borkowska-Klos M, Atkinson APM, Szala A, Jopek A, Jensenius JC, Kawakami M, Szczapa J, Matsushita M, Szemraj J, Turner ML, Kilpatrick DC (2009) Mannan-binding lectin-associated serine protease-2 (MASP-2) in a large cohort of neonates and its clinical associations. Mol Immunol 46:1696–1701CrossRef
25.
Presanis J, Hajela K, Ambrus G, Gal P, Sim RB (2004) Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol 40:921–929PubMedCrossRef
26.
Kilpatrick DC (2007) Clinical significance of mannan-binding lectin and L-ficolin. In: Kilpatrick D (ed) Collagen-related lectins in innate immunity. Research Signpost, Trivandrum, pp 57–84
27.
Heitzeneder S, Seidel M, Forster-Waldl E, Heitiger A (2012) Mannan-binding lectin deficiency—good news, bad news, doesn’t matter? Clin Immunol 143:22–38PubMedCrossRef
28.
Bak-Romaniszyn L, Szala A, Sokolowska A, Mierzwa G, Czerwionka-Szaflarska M, Swierzko ASt, Zeman K, Cedzynski M (2011) Mannan-binding lectin deficiency in pediatric patients with inflammatory bowel disease. Scand J Gastroenterol 46:1275–1278PubMedCrossRef
29.
Li YL, Ye F, Hu Y, Lu WG, Xie X (2009) Identification of suitable reference genes for gene expression studies of human serous ovarian cancer by real-time polymerase chain reaction. Anal Biochem 394:110–116PubMedCrossRef
30.
Winer J, Jung CK, Shackel I, Williams PM (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:41–49PubMedCrossRef
31.
Wigginton JE, Cutler DJ, Abecasis GR (2005) A note on exact tests of Hardy–Weinberg equilibrium. Am J Hum Genet 76:883–887CrossRef
32.
33.
Nevadunsky NS, Korneeva I, Caputo T, Witkin SS (2012) Mannose-binding lectin codon 54 genetic polymorphism and vaginal protein levels in women with gynecologic malignancies. Eur J Obstet Gynecol Reprod Biol 163:216–218PubMedCrossRef
34.
Baccarelli A, Hou L, Chen J, Lissowska J, El-Omra EM, Grillo P, Giacomini SM, Yaeger M, Bernig T, Zatonski W, Fraumeni JF Jr, Chanock SJ, Chow WH (2006) Mannose-binding lectin-2 genetic variation and stomach cancer risk. Int J Cancer 119:1970–1975PubMedCrossRef
35.
Scudiero O, Nardone G, Omodei D, Tatangelo F, Vitale DF, Dalvatore F, Castaldo G (2006) A mannose-binding lectin-defective haplotype is a risk factor for gastric cancer. Clin Chem 52:1625–1626PubMedCrossRef
36.
Eurich D, Boas-Knoop S, Morawietz L, Neuhaus R, Somasundaram R, Ruehl M, Neumann UP, Neuhaus P, Bahra M, Seehofer D (2011) Association of mannose-binding lectin-2 gene polymorphism with the development of hepatitis C-induced hepatocellular carcinoma. Liver Int 31:1006–1012PubMedCrossRef
37.
Zanetti KA, Haznadar M, Welsh JA, Robles AI, Ryan BM, McClary AC, Bowman ED, Goodman JE, Bernig T, Chanock SJ, Harris CC (2012) 3′-UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon cancer risk in African Americans. Cancer Res 72:1467–1477PubMedCrossRefPubMedCentral
38.
Michaud DS, Siddig A, Cox DG, Backes DM, Calboli FC, Sughrue ME, Gaziano JM, Ma J, Stampfer M, Tworoger SS, Hunter DJ, Camargo CA Jr, Parsa AT (2013) Mannose-binding lectin 2 gene and risk of adult glioma. PLoS ONE 8:e61117PubMedCrossRefPubMedCentral
39.
Schmiegelow K, Garred P, Lausen B, Andreassen B, Petersen BL, Madsen HO (2002) Increased frequency of mannose-binding lectin insufficiency among children with acute lymphoblastic leukemia. Blood 100:3757–3760PubMedCrossRef
40.
Ytting H, Christensen IJ, Steffensen R, Alsner J, Thiel S, Jensenius JC, Hansen U, Nielsen HJ (2011) Mannan-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) genotypes in colorectal cancer. Scand J Immunol 73:122–127PubMedCrossRef
41.
Shi Y, Liu G, Zhang H, Yu F, Xiang X, Lu Y, Dong X, Li X (2013) Expressions and clinical significances of mannose-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) in patients with thyroid neoplasm. Chin Ger J Clin Oncol 12:106–108CrossRef
42.
Ytting H, Christensen IJ, Thiel S, Jensenius JC, Nielsen HJ (2005) Serum mannan-binding lectin-associated serine protease 2 levels in colorectal cancer: relation to recurrence and mortality. Clin Cancer Res 11:1441–1446PubMedCrossRef
43.
Ytting H, Christensen IJ, Thiel S, Jensenius JC, Nielsen HJ (2008) Pre- and postoperative levels in serum mannan-binding lectin-associated serine protease-2—a prognostic marker in colorectal cancer. Hum Immunol 69:414–420PubMedCrossRef
44.
Fisch UP, Zehnder A, Hirt A, Niggli FK, Simon A, Ozsahin H, Schlapbach LJ, Ammann RA (2011) Mannan-binding lectin (MBL) and MBL-associated serine protease-2 in children with cancer. Swiss Med Wkly 141:w13191PubMed
45.
Lu Y, Sun G, Liu G, Shi Y, Han Y, Yu F, Xiang X, Li W, Xiao H, Liu X, Sha L (2013) Clinical significance of mannose-binding lectin expression in thyroid carcinoma tissues. Pathol Oncol Res 19:259–266PubMedCrossRef
Metadata
Title
Mannose-Binding Lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours
Authors
Anna St. Swierzko
Agnieszka Szala
Sambor Sawicki
Janusz Szemraj
Marcin Sniadecki
Anna Sokolowska
Andrzej Kaluzynski
Dariusz Wydra
Maciej Cedzynski
Publication date
01-11-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 11/2014
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-014-1579-y

Other articles of this Issue 11/2014

Cancer Immunology, Immunotherapy 11/2014 Go to the issue

Letter to the Editors

Limited efficacy of intratumoral IL-2 applied to large melanoma metastases

Original Article

AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction

Original Article

CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma

Review

A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response

Original Article

FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells

Original Article

A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits